12 fasudil hydrochloride synthesis pharmacological and clinical research advances.docVIP

 PAGE \* MERGEFORMAT 27 12 fasudil hydrochloride synthesis pharmacological and clinical research advances [Keywords:] fasudil hydrochloride; synthesis; pharmacology; clinical Fasudil hydrochloride (Fasudil Hydrochloride, Fasudil, HA1077, AT877) its chemical name: hexahydro 1 (5 isoquinoline sulfonyl) 1 (H) 1,4 diaza hydrochloride, English name: Hexahydro 1 ( 5 isoquinolinesulfonyl) 1H 1,4 diazepine hydrochloride, molecular formula: C14H17N3O2S HCl, is Japan’s Asahi Chemical Company in 1994, listing a new brand name Eril calcium antagonistic vasodilators, for the treatment of cerebral vasospasm caused by spider membrane hemorrhage. The product for the treatment of acute ischemic stroke, sequelae of cerebrovascular disease and angina pectoris in clinical trials the efficacy is [1-4]. 1 Advances in research and development at home and abroad [5] 1.1 domestic and international market conditions since the late 90s of last century, cardiovascular disease has gradually become the first cause of death of urban and rural residents, which currently represents nearly 40% of deaths. The area was mainly due to atherosclerosis disease, diabetes, poor lipid hyperlipidemia, hypertension and obesity and other factors. as foreign patent expiry of several major products, with several new products coming soon, will make the big breakthrough occurred in the market change. more manufacturers preference to the more complex therapeutic agents, in particular, their development is considered to extend the life of mature products pharmaceuticals market growth and expansion of the whole way. Moreover, consumers prefer the therapeutic compound, as eliminating the inconvenience of taking many pills and improve the patient the possibility of recovery. According to Datamonitor’s latest report, in 2007 the world’s cardiovascular drug market will be worth over 52 billion U.S. dollars, China’s pharmaceutical market conditions the cardiovascular system in Table 1. Table 1 shows, c